Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19057077 | 0.81 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL19593581 | 0.81 | PTGS1 (0.31) | PTGS1PTGS2 | |
| SCHEMBL20125607 | 0.78 | GAA (0.32) | PTGS1PTGS2 | |
| SCHEMBL17761929 | 0.78 | S1PR1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL19418897 | 0.78 | NPSR1 (0.34) | — | |
| SCHEMBL17761937 | 0.78 | — | — | |
| SCHEMBL19057079 | 0.78 | P2RX7 (0.30) | — | |
| SCHEMBL25864290 | 0.76 | — | — | |
| SCHEMBL23072107 | 0.73 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL25971962 | 0.71 | POLB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968360-B1 | QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3730487-A1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | Gilead Sciences, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-08-27 | — | — | US | disclosed |
| US-10307407-B2 | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2018-05-17 | — | — | US | disclosed |
| US-20180036294-A1 | 9H-PYRIMIDO [4,5-B] INDOLES AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2018-02-08 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-9580430-B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | BRD4, BET1, BRWD1 | PTGS1 3611/4885PTGS2 4145/4885 |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | PTGS1 4146/4885PTGS2 4346/4885 |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | MDM2, CD74, TNFSF10 | PTGS1 4146/4885PTGS2 4346/4885 |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | PTGS1 1155/4885PTGS2 2152/4885 |
| US-10391175-B2 | BET bromodomain inhibitors and therapeutic methods using the same | BRD4, BRDT, BRD3 | PTGS1 3018/4885PTGS2 3195/4885 |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | PTGS1 3729/4885PTGS2 4024/4885 |
| US-10307407-B2 | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | PTGS1 1613/4885PTGS2 2589/4885 |
| US-20180036294-A1 | 9H-PYRIMIDO [4,5-B] INDOLES AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | PTGS1 1613/4885PTGS2 2589/4885 |
| US-20180134715-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | PTGS1 3729/4885PTGS2 4024/4885 |
| US-10253044-B2 | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | PTGS1 1155/4885PTGS2 2152/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | PTGS1 3018/4885PTGS2 3195/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | PTGS1 3018/4885PTGS2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.